Rhynchophylline, a NMDA antagonist found in kratom, poses neuroprotective benefits through the regulation of Akt/mTOR and TLRs signaling pathways.
mdpi.com/1420-3049/19/8/11196/htmPosted Jun 26, 2017, 5:38 PM UTC
Posted Jun 26, 2017, 5:38 PM UTC
Worth noting that it is apparently found more in some Uncaria species, if you're interested in it but not the rest of the kratom alkaloids:
Rhynchophylline
Rhynchophylline is an alkaloid found in certain Uncaria species (Rubiaceae), notably Uncaria rhynchophylla and Uncaria tomentosa. It also occurs in the leaves of Mitragyna speciosa (kratom), a tree native to Thailand. Chemically, it is related to the alkaloid mitragynine.
Rhynchophylline is a non-competitive NMDA antagonist (IC50 = 43.2 μM) and a calcium channel blocker.
^[ ^PM ^| ^Exclude ^me ^| ^Exclude ^from ^subreddit ^| ^FAQ ^/ ^Information ^] ^Downvote ^to ^remove ^| ^v0.23
the neuroprotective effect of Rhy was investigated in a stroke model
Um, not to be a downer, but don't pretty much all NMDA antagonists have a protective effect in animal stroke models? Nothing to get excited about.
Nice to see a novel one in an herb with many other beneficial properties, though.
It's like finding out your pure organic compound was a white solid - what else did you expect? ;)
[deleted]
Is there any nmda antagonists in trial indicated for depression? Apart from memantine.
Ketamine, for one
I remember seeing a study on this sub a long time ago that said the anti-depressive effects of ketamine were actually from a metabolite that acts on glutamate receptors, not NMDA. https://www.nih.gov/news-events/news-releases/ketamine-lifts-depression-byproduct-its-metabolism
Sure, but it's not incorrect to say that ketamine is being investigated for antidepressant effects.
I'm personally a little leery of that claim. I'm in the Rick Doblin camp, that assumes that some of the beneficial and therapeutic uses of these drugs depend in part on psychoactive effects.
I can attest to the therapeutic effects of ketamine being from the psychedelic experience itself. The clinic I went to for my ketamine infusions focused on having the patients reach PTR (psychotropic therapeutic response). Most clinics only dose up to 75mg, but the clinic I went to dosed me up to 150 mg (IV). I can tell you that it worked as advertised.
I know there are a few clinical trials for GSK3 inhibitors for Alzheimer at the moment. GSK3 seem to be a key regulator in NMDA receptor channels. Which is also proposed as a partial mechanism of action of rhynchophylline.
Last year they found a new way of making compounds these kinase enzymes. Which is needed because the current GSK3-active compounds also hit other things which is why many compounds failed in clinical trials.
With the many substrates I am sure this will be a focus in the future.
I tried to get in a depression drug trial for something called glyx-13, which is supposed to work like ketamine. It was in New York. From memory, there are 3 the FDA fast tracked last year.